select a format

Single User License
USD 250 INR 16198
Site License
USD 500 INR 32395
Corporate User License
USD 750 INR 48593

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


OPKO Health Inc (OPK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

OPKO Health Inc (OPK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH41384D
  • |
  • Pages: 111
  • |
  • July 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

OPKO Health Inc (OPKO) is a biopharmaceutical and diagnostic company. It discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals. The company's product portfolio includes point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It offers products and vaccines that are used in the treatment of chronic kidney disease, Parkinson's disease, asthma, hemophilia, obesity, chronic obstructive pulmonary disease (COPD) and chemotherapy-induced nausea and vomiting, among others. The company also offers contract research services to other pharmaceutical companies. The company has its operational presence with its offices located in Chile, Mexico, Spain, Ireland, Canada and Israel. OPKO is headquartered in Miami, Florida, the US.

OPKO Health Inc (OPK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

OPKO Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

OPKO Health Inc, Medical Devices Deals, 2011 to YTD 2017 13

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

OPKO Health Inc, Pharmaceuticals & Healthcare, Deal Details 19

Venture Financing 19

Eloxx Pharma Raises Additional USD6 Million in Series C Financing 19

Partnerships 20

Transition Therapeutics Enters into Agreement with Brigham and Women's Hospital 20

BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 20

Perrigo Amends Development And Commercialization Agreement With Transition Therapeutics For ELND005 21

Prolor Biotech Plans To Enter Into Commercialization Agreement For Longer-Acting Growth Hormone 22

EirGen Pharma Enters into Agreement with Equity Pharma 23

Licensing Agreements 24

Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 24

OPKO Health Enters into Licensing Agreement with Scripps Research Institute 24

Transition Therapeutics Enters into Licensing Agreement with Eli Lilly for TT701 25

Opko Health Enters into Licensing Agreement with Pfizer 26

Opko Health Enters into Licensing Agreement with DSG 28

Transition Therapeutics Enters Into Licensing Agreement With Eli Lilly For TT-601 28

Transition Therapeutics and Eli Lilly Amend Licensing Agreement 29

Opko Health Enters Into Licensing Agreement With Pharmsynthez 31

Opko Health Enters Into Licensing Agreement For Ranibizumab 32

OPKO Health Enters Into Licensing Agreement With Scripps Research Institute For SR 3306 32

OPKO Health Enters Into Licensing Agreement With BioZone Pharma For Drug Delivery Platforms 33

OPKO Health Enters Into Licensing Agreement With ChromaDex 34

PROLOR Biotech Enters Into Licensing Agreement With Yeda Research 35

Equity Offering 36

Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 36

Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 37

VBI Vaccines Raises USD13.6 Million in Private Placement of Shares 38

Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 40

Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 41

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 42

Transition Therapeutics Raises USD23 Million in Public Offering of Shares 44

Transition Therapeutics Raises USD17 Million in Private Placement of Units 45

BioZone Pharma Completes Private Placement Of Shares For USD2.8 Million 46

Arno Therapeutics Completes Private Placement Of Units For USD30.7 Million 47

Farmsintez Announces Private Placement Of Shares For USD32.9 Million 49

Transition Therapeutics Completes Private Placement Of Shares For USD11 Million 49

RXi Pharma Completes Private Placement Of Shares For USD16 Million 50

Prolor Biotech Completes Public Offering Of Common Stock For USD37 Million 51

ChromaDex Completes Private Placement Of Common Stock For USD3.7 Million 53

Transition Therapeutics Completes Non-Brokered Private Placement Of Shares For USD5 Million 54

OPKO Health Completes Exercise Of Underwriters' Over-allotment Option For USD110 Million 55

Debt Offering 57

Opko Health Completes Private Placement Of Notes Due 2033 For USD175 Million 57

Asset Transactions 58

RXi Pharma Acquires RNAi-Related Assets from Opko Health 58

Acquisition 59

OPKO Health Acquires 5.11% Stake in RXi Pharma 59

OPKO Health Acquires Transition Therapeutics for USD60 Million 60

OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 62

Opko Health Acquires Bio-Reference Labs 62

OPKO Health Acquires EirGen Pharma for USD135 Million 64

Opko Health Acquires Inspiro Medical 65

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD15 Million 66

Opko Health Completes Acquisition Of Laboratorio Arama 67

Opko Health To Acquire Stake In Zebra Biologics 67

Opko Health Completes Acquisition Of Prolor Biotech For Up To USD480 Million 68

BioReference Labs To Acquire Edge Bioserv From Edge BioSystems 70

BioReference Labs Acquires Hunter Labs 71

Opko Health Acquires 10% Stake In Pharmsynthez, Life Science Company 72

Opko Health Completes Acquisition Of Cytochroma For Up To USD290 Million 73

Opko Health Completes Acquisition Of Silcon Comercio 75

Opko Health Completes Acquisition Of Oppenheimer Urologic Reference Laboratory For USD40 Million 76

Opko Health Acquires Farmadiet For USD16.6 Million 76

Opko Health To Acquire 45% Stake In SciGen Israel From FDS Pharma 78

OPKO Health Completes Acquisition Of ALS Distribuidora For USD4 Million 78

SPIMACO Acquires 48% Stake In EirGen Pharma, Manufacturer Of Cytotoxic Pharmaceutical Products, For USD25.3 Million 79

OPKO Health Completes Acquisition Of Drug Ingredients Maker FineTech For USD27.5 Million 80

OPKO Health Acquires CURNA 81

OPKO Health Inc-Key Competitors 83

Key Employees 84

Locations And Subsidiaries 85

Head Office 85

Other Locations & Subsidiaries 85

Recent Developments 88

Financial Announcements 88

May 09, 2017: OPKO Health Reports 2016 Financial and Operating Results 88

Mar 01, 2017: OPKO Health Reports 2016 Financial and Operating Results 89

Nov 07, 2016: OPKO Health Reports Third Quarter Financial and Operating Results 91

Aug 08, 2016: OPKO Health Reports Improved Financial and Operating Results 93

May 09, 2016: OPKO Health Reports First Quarter Financial and Operating Results 94

Feb 29, 2016: OPKO Announces Financial and Operating Results 96

Corporate Communications 98

Feb 07, 2017: OPKO Health names new chief commercial officer for renal division 98

Dec 19, 2016: OPKO Health to be Added to the NASDAQ Biotechnology Index 100

Sep 13, 2016: OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories 101

Jun 13, 2016: OPKO Health Announces Move to NASDAQ Stock Market 102

Mar 15, 2016: OPKO Health Names Dr. Gregory Henderson President of Bio-Reference Laboratories 103

Feb 29, 2016: OPKO's GeneDx Recognizes International Rare Disease Day with Donation of Free Exome Tests to Syndromes Without a Name 104

Government and Public Interest 105

Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD 105

Product News 106

Apr 18, 2016: Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401 106

Product Approvals 107

Mar 22, 2017: OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 107

Mar 08, 2017: OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 108

Clinical Trials 109

Apr 25, 2016: Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 109

Feb 01, 2016: Transition Therapeutics Announces Top Line Phase 2 Clinical Study Results of Diabetes Drug Candidate TT401 110

Appendix 111

Methodology 111

About GlobalData 111

Contact Us 111

Disclaimer 111

List of Figures

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

OPKO Health Inc, Medical Devices Deals, 2011 to YTD 2017 13

List of Tables

OPKO Health Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

OPKO Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

OPKO Health Inc, Deals By Therapy Area, 2011 to YTD 2017 11

OPKO Health Inc, Medical Devices Deals, 2011 to YTD 2017 13

OPKO Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Eloxx Pharma Raises Additional USD6 Million in Series C Financing 19

Transition Therapeutics Enters into Agreement with Brigham and Women's Hospital 20

BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 20

Perrigo Amends Development And Commercialization Agreement With Transition Therapeutics For ELND005 21

Prolor Biotech Plans To Enter Into Commercialization Agreement For Longer-Acting Growth Hormone 22

EirGen Pharma Enters into Agreement with Equity Pharma 23

Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 24

OPKO Health Enters into Licensing Agreement with Scripps Research Institute 24

Transition Therapeutics Enters into Licensing Agreement with Eli Lilly for TT701 25

Opko Health Enters into Licensing Agreement with Pfizer 26

Opko Health Enters into Licensing Agreement with DSG 28

Transition Therapeutics Enters Into Licensing Agreement With Eli Lilly For TT-601 28

Transition Therapeutics and Eli Lilly Amend Licensing Agreement 29

Opko Health Enters Into Licensing Agreement With Pharmsynthez 31

Opko Health Enters Into Licensing Agreement For Ranibizumab 32

OPKO Health Enters Into Licensing Agreement With Scripps Research Institute For SR 3306 32

OPKO Health Enters Into Licensing Agreement With BioZone Pharma For Drug Delivery Platforms 33

OPKO Health Enters Into Licensing Agreement With ChromaDex 34

PROLOR Biotech Enters Into Licensing Agreement With Yeda Research 35

Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 36

Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 37

VBI Vaccines Raises USD13.6 Million in Private Placement of Shares 38

Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 40

Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 41

MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 42

Transition Therapeutics Raises USD23 Million in Public Offering of Shares 44

Transition Therapeutics Raises USD17 Million in Private Placement of Units 45

BioZone Pharma Completes Private Placement Of Shares For USD2.8 Million 46

Arno Therapeutics Completes Private Placement Of Units For USD30.7 Million 47

Farmsintez Announces Private Placement Of Shares For USD32.9 Million 49

Transition Therapeutics Completes Private Placement Of Shares For USD11 Million 49

RXi Pharma Completes Private Placement Of Shares For USD16 Million 50

Prolor Biotech Completes Public Offering Of Common Stock For USD37 Million 51

ChromaDex Completes Private Placement Of Common Stock For USD3.7 Million 53

Transition Therapeutics Completes Non-Brokered Private Placement Of Shares For USD5 Million 54

OPKO Health Completes Exercise Of Underwriters' Over-allotment Option For USD110 Million 55

Opko Health Completes Private Placement Of Notes Due 2033 For USD175 Million 57

RXi Pharma Acquires RNAi-Related Assets from Opko Health 58

OPKO Health Acquires 5.11% Stake in RXi Pharma 59

OPKO Health Acquires Transition Therapeutics for USD60 Million 60

OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 62

Opko Health Acquires Bio-Reference Labs 62

OPKO Health Acquires EirGen Pharma for USD135 Million 64

Opko Health Acquires Inspiro Medical 65

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD15 Million 66

Opko Health Completes Acquisition Of Laboratorio Arama 67

Opko Health To Acquire Stake In Zebra Biologics 67

Opko Health Completes Acquisition Of Prolor Biotech For Up To USD480 Million 68

BioReference Labs To Acquire Edge Bioserv From Edge BioSystems 70

BioReference Labs Acquires Hunter Labs 71

Opko Health Acquires 10% Stake In Pharmsynthez, Life Science Company 72

Opko Health Completes Acquisition Of Cytochroma For Up To USD290 Million 73

Opko Health Completes Acquisition Of Silcon Comercio 75

Opko Health Completes Acquisition Of Oppenheimer Urologic Reference Laboratory For USD40 Million 76

Opko Health Acquires Farmadiet For USD16.6 Million 76

Opko Health To Acquire 45% Stake In SciGen Israel From FDS Pharma 78

OPKO Health Completes Acquisition Of ALS Distribuidora For USD4 Million 78

SPIMACO Acquires 48% Stake In EirGen Pharma, Manufacturer Of Cytotoxic Pharmaceutical Products, For USD25.3 Million 79

OPKO Health Completes Acquisition Of Drug Ingredients Maker FineTech For USD27.5 Million 80

OPKO Health Acquires CURNA 81

OPKO Health Inc, Key Competitors 83

OPKO Health Inc, Key Employees 84

OPKO Health Inc, Other Locations 85

OPKO Health Inc, Subsidiaries 85

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

OPKO Health Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com